Overcoming cancer therapeutic bottleneck by drug repurposing

Z Zhang, L Zhou, N **e, EC Nice, T Zhang… - Signal transduction and …, 2020 - nature.com
Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated
the development of the alternative strategy of drug repurposing, the development of old …

Determinants of relapse periodicity in Plasmodium vivax malaria

NJ White - Malaria journal, 2011 - Springer
Plasmodium vivax is a major cause of febrile illness in endemic areas of Asia, Central and
South America, and the horn of Africa. Plasmodium vivax infections are characterized by …

Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination

T Bousema, C Drakeley - Clinical microbiology reviews, 2011 - journals.asm.org
Malaria remains a major cause of morbidity and mortality in the tropics, with Plasmodium
falciparum responsible for the majority of the disease burden and P. vivax being the …

The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread

CJ Woodrow, NJ White - FEMS microbiology reviews, 2017 - academic.oup.com
Artemisinins are the most rapidly acting of currently available antimalarial drugs. Artesunate
has become the treatment of choice for severe malaria, and artemisinin-based combination …

Primaquine: the risks and the benefits

EA Ashley, J Recht, NJ White - Malaria journal, 2014 - Springer
Primaquine is the only generally available anti-malarial that prevents relapse in vivax and
ovale malaria, and the only potent gametocytocide in falciparum malaria. Primaquine …

Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue

SH Adjalley, GL Johnston, T Li, RT Eastman… - Proceedings of the …, 2011 - pnas.org
Clinical studies and mathematical models predict that, to achieve malaria elimination,
combination therapies will need to incorporate drugs that block the transmission of …

Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an …

TJ Peto, R Tripura, JJ Callery, D Lek… - The Lancet Infectious …, 2022 - thelancet.com
Background Late treatment failures after artemisinin-based combination therapies (ACTs) for
falciparum malaria have increased in the Greater Mekong subregion in southeast Asia …

Reduced Susceptibility of Plasmodium falciparum to Artesunate in Southern Myanmar

MP Kyaw, MH Nyunt, K Chit, MM Aye, KH Aye, MM Aye… - PloS one, 2013 - journals.plos.org
Background Plasmodium falciparum resistance to artemisinins, the first line treatment for
malaria worldwide, has been reported in western Cambodia. Resistance is characterized by …

Advances and roadblocks in the treatment of malaria

B Hanboonkunupakarn, NJ White - British journal of clinical …, 2022 - Wiley Online Library
The deployment of artesunate for severe malaria and the artemisinin combination therapies
(ACTs) for uncomplicated malaria has been a major advance in antimalarial therapeutics …

The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study

S Dini, NM Douglas, JR Poespoprodjo, E Kenangalem… - BMC medicine, 2020 - Springer
Background An acute episode of malaria can be followed by multiple recurrent episodes
either due to re-infection, recrudescence of a partially treated parasite or, in the case of …